Analysts expect Travere Therapeutics, Inc. to report revenue of 202.43 M for Q3 26, against a range of 184.69 M to 220.16 M. The most recent reported quarter, Q2 26, came in at 169.58 M, a 15.0% beat against the 147.44 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 62.90 M | 73.55 M | 75.86 M | 94.84 M | 164.86 M | 129.69 M | 127.20 M | 169.58 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 69.75 M | 73.29 M | 79.77 M | 114.51 M | 113.91 M | 146.97 M | 136.72 M | 153.76 M | 220.16 M | 263.81 M | 244.14 M | 300.96 M | 355.13 M | 376.55 M | 280.28 M | 297.16 M | ||||||||||
| Low Estimate | 58.31 M | 64.02 M | 68.74 M | 95.16 M | 106.74 M | 124.30 M | 120.06 M | 141.11 M | 184.69 M | 223.33 M | 226.84 M | 268.28 M | 323.92 M | 327.54 M | 260.68 M | 265.73 M | ||||||||||
| Consensus Estimate | 64.03 M | 68.65 M | 74.25 M | 104.84 M | 110.33 M | 135.63 M | 128.39 M | 147.44 M | 202.43 M | 243.57 M | 235.49 M | 284.62 M | 339.53 M | 352.05 M | 270.48 M | 281.45 M |
Analysts expect Travere Therapeutics, Inc. to report earnings per share of 0.03 for Q3 26, against a range of 0.03 to 0.03. The most recent reported quarter, Q2 26, came in at -0.37, a 208.3% miss against the -0.12 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.70 | -0.73 | -0.47 | -0.14 | 0.28 | 0.03 | -0.40 | -0.37 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.67 | -0.56 | -0.57 | -0.29 | -0.29 | 0.00 | -0.23 | -0.11 | 0.03 | 0.56 | 0.63 | 0.91 | 0.90 | 1.14 | 1.03 | 1.07 | ||||||||||
| Low Estimate | -0.75 | -0.64 | -0.61 | -0.31 | -0.35 | 0.00 | -0.27 | -0.13 | 0.03 | 0.50 | 0.55 | 0.75 | 0.84 | 1.02 | 0.89 | 0.95 | ||||||||||
| Consensus Estimate | -0.71 | -0.60 | -0.59 | -0.30 | -0.32 | 0.00 | -0.25 | -0.12 | 0.03 | 0.53 | 0.59 | 0.83 | 0.87 | 1.08 | 0.96 | 1.01 |
Pull Wall Street consensus for Travere Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=TVTX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "TVTX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=TVTX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();